Roman Urfer, PhD - Selonterra, Inc. - Chief Executive Officer

Roman Urfer

PhD

Selonterra, Inc.

Chief Executive Officer

Belmont, California | United States

Main Specialties: Pharmacology

Additional Specialties: Drug Discovery & Development

Roman Urfer, PhD - Selonterra, Inc. - Chief Executive Officer

Roman Urfer

PhD

Introduction

Primary Affiliation: Selonterra, Inc. - Belmont, California , United States

Specialties:

Additional Specialties:

Research Interests:

Education

Feb 1992
University of Basel
PhD
Biochemistry
Jul 1989
ETH Zurich
MSc

Publications

18Publications

347Reads

2Profile Views

14PubMed Central Citations

Identification of a Nuclear Respiratory Factor 1 Recognition Motif in the Apolipoprotein E Variant APOE4 linked to Alzheimer's Disease.

Sci Rep 2017 01 17;7:40668. Epub 2017 Jan 17.

Selonterra LLC, 1025 Alameda de las Pulgas, Suite 126, Belmont CA 94002, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep40668DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240558PMC
January 2017
1 Read
5.080 Impact Factor

Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke.

Stroke 2014 Nov 30;45(11):3304-10. Epub 2014 Sep 30.

From the M's Science Corporation, Kobe, Japan (R.U., W.S., S.M.); Moebius-Consult GmbH, Zurich, Switzerland (H.J.M.); Department of Neurology, University Hospital Ostrava, Ostrava, Czech Republic (D.S.); Neurovascular Unit, Hospital Vall Hebron, Barcelona, Spain (E.S.); and Institute of Neuroscience and Psychology, University of Glasgow, Southern General Hospital, Glasgow, Scotland, United Kingdom (K.W.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/STROKEAHA.114.005835DOI Listing
November 2014
45 Reads
11 Citations
5.723 Impact Factor

A pharmacological screening approach for discovery of neuroprotective compounds in ischemic stroke.

PLoS One 2013 18;8(7):e69233. Epub 2013 Jul 18.

Behavioral and Functional Neuroscience Laboratory, Institute for Neuro-Innovation and Translational Neurosciences, School of Medicine, Stanford, California, USA.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0069233PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3715457PMC
February 2014
20 Reads
3 Citations
3.234 Impact Factor

Sigma-1 receptor chaperones regulate the secretion of brain-derived neurotrophic factor.

Synapse 2012 Jul 16;66(7):630-9. Epub 2012 Mar 16.

National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health--Cellular Stress Signaling Unit and Cellular Pathobiology Section, Integrative Neuroscience Branch, Baltimore, Maryland 21224, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/syn.21549DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824965PMC
July 2012
7 Reads
2.130 Impact Factor

Npas4, a novel helix-loop-helix PAS domain protein, is regulated in response to cerebral ischemia.

Eur J Neurosci 2006 Nov;24(10):2705-20

AGY Therapeutics, South San Francisco, California 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1460-9568.2006.05172.xDOI Listing
November 2006
10 Reads
3.181 Impact Factor

Regulation of NMDA receptor trafficking and function by striatal-enriched tyrosine phosphatase (STEP).

Eur J Neurosci 2006 Jun;23(11):2847-56

AGY Therapeutics Inc, 270 E. Grand Avenue, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1460-9568.2006.04837.xDOI Listing
June 2006
26 Reads
3.181 Impact Factor

Discoidin domain receptor-1a (DDR1a) promotes glioma cell invasion and adhesion in association with matrix metalloproteinase-2.

J Neurooncol 2006 Feb;76(3):239-48

AGY Therapeutics, Inc., 270 East Grand Avenue, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-005-6874-1DOI Listing
February 2006
70 Reads
3.070 Impact Factor

Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model.

Cancer Res 2006 Feb;66(4):2271-8

AGY Therapeutics, Inc., South San Francisco, California 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-05-1221DOI Listing
February 2006
1 Read
9.330 Impact Factor

Death-associated protein kinase is activated by dephosphorylation in response to cerebral ischemia.

J Biol Chem 2005 Dec 3;280(51):42290-9. Epub 2005 Oct 3.

AGY Therapeutics, Inc., South San Francisco, California 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M505804200DOI Listing
December 2005
15 Reads
4.573 Impact Factor

FAS associated phosphatase (FAP-1) blocks apoptosis of astrocytomas through dephosphorylation of FAS.

J Neurooncol 2005 Sep;74(3):241-8

AGY Therapeutics Inc., Drug Discovery, 270 East Grand Avenue, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-004-7202-xDOI Listing
September 2005
4 Reads
3.070 Impact Factor

Linking solubility and permeability assays for maximum throughput and reproducibility.

J Biomol Screen 2005 Jun;10(4):383-90

Lead Discovery Department, AGY Therapeutics Inc., South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1087057105274785DOI Listing
June 2005
32 Reads
2.423 Impact Factor

Functional comparison of long and short splice forms of RPTPbeta: implications for glioblastoma treatment.

Neuro Oncol 2005 Apr;7(2):154-63

AGY Therapeutics, Inc., 270 East Grand Avenue, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1215/S1152851704000547DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1871891PMC
April 2005
3 Reads
5.562 Impact Factor

GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion.

Oncogene 2005 Mar;24(10):1673-82

AGY Therapeutics Inc., 270 East Grand Avenue, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1208395DOI Listing
March 2005
7 Reads
8.460 Impact Factor

A high-throughput turbidometric assay for screening inhibitors of protein disulfide isomerase activity.

J Biomol Screen 2004 Oct;9(7):614-20

Lead Discovery Department, AGY Therapeutics Inc, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1087057104265292DOI Listing
October 2004
8 Reads
2.423 Impact Factor